|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/50 | |
| A61K 9/28 | |||
| A61K 31/506 | |||
| A61K 31/519 | |||
| A61K 9/48 |
| (11) | Patento numeris | 3236953 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15826209.7 |
| Europos patento paraiškos padavimo data | 2015-12-23 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-11-01 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-11-11 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/000303 |
| Data | 2015-12-23 |
| (87) | Numeris | WO 2016/105531 |
| Data | 2016-06-30 |
| (30) | Numeris | Data | Šalis |
| 201462096809 P | 2014-12-24 | US |
| (72) |
NUNN, Philipp, US
BERNER, Bret, US
MASJEDIZADEH, Mohammad, US
|
| (73) |
Principia Biopharma Inc.,
220 E. Grand Ave., S. San Francisco, CA 94080,
US
|
| (54) | SITE SPECIFIC DOSING OF A BTK INHIBITOR |
| SITE SPECIFIC DOSING OF A BTK INHIBITOR |